Author: oncologs.com

A significant survival improvement for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia is published today by the New England Journal of Medicine. The practice-changing finding is from the randomized phase 3 study E1910 (NCT02003222), which evaluated blinatumomab immunotherapy in patients who were

Reston, VA—Two reduced dose radiopharmaceutical therapy approaches for advanced stage metastatic castrate-resistant prostate cancer have been shown to be just as effective as the standard dose, according to new research published in the July issue of The Journal of Nuclear Medicine. Treatment with deescalated 225Ac-PSMA-617 or a

Receptor protein tyrosine phosphatases are cell membrane-localised proteins. They are regulators of cell-cell contacts and are also considered likely to be tumour suppressors but the specifics of how they function are unknown. A member of this family, PTPRK, is implicated as a tumour suppressor in

PLYMOUTH MEETING, PA [July 24, 2024] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—commemorates the 25th anniversary of the NCCN Oncology Research Program (ORP). The NCCN ORP is dedicated to seeking innovative, effective, and equitable cancer care through oversight and funding

As part of a breast cancer diagnosis, pathologists take cells from a biopsy and check them under a microscope. Most cancerous cells form roundish clumps, known as no special type, or invasive ductal carcinoma (IDC). In fewer patients, the abnormal cells are more dispersed, growing

Abu Dhabi, July 22, 2024: A team of researchers at NYU Abu Dhabi, led by Professor Sehamuddin Galadari, has discovered that the tumor suppressor protein Prostate apoptosis response-4 (Par-4) can cause a unique type of cell death called ferroptosis in human glioblastoma – the most

BUFFALO, NY – July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry. Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff,

A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer – and could potentially be applied to fibrotic conditions like liver fibrosis or pulmonary fibrosis.  Credit: MUSC Hollings Cancer Center A new compound developed

A team of researchers from Henan University of Science and Technology have introduced a  novel method for improving drug testing for esophageal cancer (EC) using advanced three-dimensional (3D) cell culture technology. The authors created a tumor spheroid model on a chip by using inverse opal

“Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.” Credit: 2024 Jackovich et al. “Future development for sEphB4-HSA in HNSCC is likely to focus on patients